Polyomavirus BK nephropathy in renal-transplant recipients represents a secondary infection linked with rejection and its treatment that can, in most cases, be monitored by measuring the viral load in plasma, suggests a new prospective study.
Nephropathy associated with the polyomavirus type BK (BKV) has emerged as an important cause of allograft failure in renal-transplant recipients since it was first reported in 1995, say the authors. It may be linked to immunosuppressive regimens containing tacrolimus or mycophenolate mofetil and potential markers for this infection include viral inclusions, known as “decoy cells” in urine, and the presence of BKV DNA in plasma. However, there has been little prospective data to support this.
Dr Hans H. Hirsch and colleagues from University of Basel, Basel, Switzerland, and the Central Public Health Laboratory, London, England conducted a prospective, single centre study on 78 renal- transplant recipients receiving immunosuppressive therapy that included tacrolimus (37 patients) or mycophenolate mofetil (41 patients).
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!